NETRIS Pharma

NETRIS Pharma is a clinical-stage company dedicated to designing and developing anti-cancer therapeutic molecules, particularly monoclonal antibodies targeting tumor treatment resistance. Its lead product, NP137, is an advanced candidate targeting netrin-1. NETRIS Pharma is evaluating it in five clinical trials in combination with chemotherapy or immunotherapy, viewing it as a new approach to overcoming resistance to these therapies.